Index

Note: Page numbers of article titles are in **boldface** type.

A

Acetaminophen, 133, 200
ADAM12, 52
Aggrecanase inhibitors, 227
Alendronate, 225
Alpha1 antiproteinase antitrypsin, 52
American College of Rheumatology, diagnostic criteria of, 127
Analgesics, 199–201
Ankle osteoarthritis, 108
Antioxidants, 204
Arthritis, Diet, and Activity Program Trial, 149
Arthroplasty, knee
  interpositional, 215
  unicompartmental, 215–217
Arthroscopy, knee, 212–213
Asporin, 52
Association studies, genetic, 51–56
Avocado-soybean unsaponifiables, 225

B

Balance, loss of, 144
Bisphosphonates, 225
Bone
  changes in, **25–35**
    adaptive, 25–28
    cysts, 30–31
  in meniscal lesions, **37–42**
    marrow edema, 30–31
    osteophytes, 31–32
    patterns of, 28–29
    structural, 25–28
    subchondral, 29–30
    tidemark advancement in, 30
    trabecular, 29–30
  pain originating in, 14–16
Bone marrow lesions, 30–31, 86
  nuclear medicine studies of, 104
  pain originating in, 15–16
Bone morphogenetic proteins, 52, 54, 56, 226
Braces, 137
   patellar, 185–189
   unloader, 181–185
Bradykinin, 87, 226

C
Calcitonin, 225
Calcitonin gene-related peptide, 86–87
Calmodulin, 52
Canes, for knee osteoarthritis, 178–181
Capsaicin, 202–203
Cartilage intermediate layer protein, 52
Cartilage oligomeric matrix protein, 52
Cathepsin inhibitors, 227
Chondrocytes
   drugs protecting, 6–7
   mechanobiology of, 5–6
Chondroitin, 204, 225
Chondroprotective agents. See Disease-modifying osteoarthritis drugs.
CLIP protein, 52
Collagen defects, 52, 55
COMP protein, 52
Computed tomography, 104–106
ConformMIS iForma device, 215
Corticosteroids, intra-articular, 203
Cysts, bone, 30–31
Cytokines
   in obesity, 147
   inhibitors of, 205

D
Diacerein, 224–225
Disease-modifying osteoarthritis drugs, 221–232
   definition of, 222
   evidence for using, 224–225
   new targets for, 225–227
   obstacles to development, 227–228
   rationale for, 222–223
Distraction, for knee osteoarthritis, 17
DMOADs. See Disease-modifying osteoarthritis drugs.
Doxycycline, 224

E
Education, on osteoarthritis, 130
Emotional factors, in pain, 91–92
Environmental factors, in pain, 92–93
EULAR, treatment recommendations of, 129
Exercise, 131, 159–175
   effects of, 160–161
   for knee osteoarthritis, 17, 149–150, 164–165
      compliance with, 169–170
      dosage of, 169
      mode of delivery for, 167
      prescription for, 166–170
      types of, 168–169
   for muscle deficits, 161–163
   for obesity, 149–150
   pain due to, 92
   prescription for, 166–170

F
Falls, in obesity, 144
Familial aggregation studies, 44–46
Fitness Arthritis in Seniors Trial, 149–150
Footwear, 92–93
Frizzled-related proteins, 53–56
FRZB protein, 53–56

G
Gait
   analysis of, in joint mechanics studies, 68–69
   in obesity, 144–147
GARP (Genetics, Arthrosis, and Progression) study, 45–46
Genetic factors, 43–64
   association studies, 51–56
   familial aggregation, 44–46
   genome-wide studies, 56–57
   in meniscal lesions, 39–40
   linkage analysis, 50–51
   twin studies, 46–50
Genetics, Arthrosis, and Progression (GARP) study, 45–46
Genome-wide studies, 56–57
Genu valgus, 183–185, 214–215
Genu varum, 183–185, 213–214
Glucosamine, 204, 225
Glutamate, in pain, 90
Ground reaction forces, in knee osteoarthritis, 178–181
Growth differentiation factors, 53

H
Hand osteoarthritis
   genetic factors in, 53–54
   obesity and, 143–144
   prevalence of, 82
Heel pain, in obesity, 146
Heel strike transient, 190

Hip osteoarthritis
  - bone marrow lesions in, 30–31
  - computed tomography in, 106
  - deformity in, 72–73
  - genetic factors in, 49, 52–54
  - prevalence of, 82
  - treatment guidelines for, 129, 132–136

Histamine, in pain, 87

HOE140 bradykinin inhibitor, 226

Human leukocyte antigens, 53–54

Hyaluronic acid, 203–204, 225

<table>
<thead>
<tr>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging, 99–123. See also specific modalities, eg, Magnetic resonance imaging.</td>
</tr>
<tr>
<td>Inflammation, 147–148</td>
</tr>
<tr>
<td>Injections, intra-articular, 134, 203–205</td>
</tr>
</tbody>
</table>
  - corticosteroids, 203
  - hyaluronic acid, 203–204
  - tumor necrosis factor inhibitors, 226 |
| Injury, osteoarthritis after, 72 |
| Insoles, 190–193 |
| Intensive Diet and Exercise for Arthritis, 150–151 |
| Interleukin(s), 53–54, 226–227 |
| Interpositional arthroplasty, 215 |
| Intra-articular injections. See Injections, intra-articular. |
| Iodothyronine deiodinases, 52 |

<table>
<thead>
<tr>
<th>J</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint mechanics, 65–80</td>
</tr>
</tbody>
</table>
  - assessment of, 66–71
  - hypotheses about, 66
  - in alignment, 71
  - in deformity, 72–73
  - in injury, 72
  - in treatment of, 73–74 |
| Joint space narrowing, radiography of, 100–101 |

<table>
<thead>
<tr>
<th>K</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinematics, 69–70</td>
</tr>
<tr>
<td>Knee, total replacement of, 217–218</td>
</tr>
<tr>
<td>Knee osteoarthritis</td>
</tr>
</tbody>
</table>
  - alignment in, 71
  - computed tomography in, 105–106
  - genetic factors in, 47–49, 52–54
  - injury-related, 72, 93
  - magnetic resonance imaging in, 107, 109–110, 114–116
  - mechanics of, 71–74
  - meniscal lesions in, 37–42 |
nuclear medicine studies of, 104
obesity and, 143–157
pathogenesis of, muscle activity and, 160–161
prevalence of, 82
protective mechanisms in, 7–12
radiography in, 99–101
treatment of
biomechanics-based, 177–198
braces for, 181–185
canes, 178–181
  exercise for, 159–175
footwear for, 92–93
guidelines for, 129, 132–136
in tibiofemoral malalignment, 181–185
insoles for, 190–193
mechanical principles of, 73–74
patellar taping or bracing for, 185–189
physiologic interventions for, 16–18
recommendations for, 129–130
surgical, 211–220. See also Osteotomy.
walkers, 178–181
ultrasonography in, 102–103

L
Lactic acid, in pain, 87
Lateral compartment arthrosis, osteotomy for, 214–215
Leucine-rich repeats and calponin homology domain, 54
Lidocaine, topical, 203
Linkage analysis, 50–51
Lipoprotein(s), low-density, 54
LRCH protein, 54

M
Magnetic resonance imaging, 106–116, 127
  in bone marrow lesions, 30–31
  in joint mechanics studies, 69–70
Matrilin, 54
Mechanical factors. See Joint mechanics.
Medial compartment arthrosis, osteotomy for, 213–214
Meniscal lesions, 37–42
  degenerative, 37–38
  genetic factors in, 39–40
  osteoarthritis and, 39
  traumatic, 37
  treatment of, 38–39
  types of, 37–38
Meniscectomy, 38–39
Metalloproteinase inhibitors, 224
Methylprednisolone, intra-articular, 203
Mineralization, 27–28
Multicenter Osteoarthritis Study, 47
Muscle function, in knee osteoarthritis, 159–175
  - activation patterns in, 162–163
  - atrophy, 162, 165
  - deficits of, 161–165
  - exercise prescription for, 166–170
  - improvements in, 165–166
  - in proprioception, 163
  - influence of activity, 160–161
  - progression and, 163–164
  - protective, 8–10

N
Nerve(s), pain originating in, 86–88
Nerve growth factor, 226
Nitric oxide synthase inhibitors, 225–226
Nociceptors, 87–88
Nonsteroidal anti-inflammatory drugs, 134, 201–202
Nuclear medicine studies, 104

O
Obesity, 143–157
  - as risk factor, 143–144
  - functional effects of, 144–147
  - gait in, 144–147
  - inflammation in, 147–148
  - weight loss for, 131, 148–152
Opioids, 200–201
Orthotics, 137. See also Braces.
Osteoarthritis
  - ankle, 108
  - constitutional factors in, 91–92
  - definition of, 1–2, 82
  - diagnosis of, 83–84, 126–127
  - differential diagnosis of, 128
  - environmental factors in, 92–93
  - evaluation of, 127–128
  - financial costs of, 81
  - genetic factors in, 39–40, 43–64
  - hand, 53–54, 82, 143–144
  - hip. See Hip osteoarthritis.
  - imaging in, 99–123. See also specific modalities, eg, Magnetic resonance imaging.
  - knee. See Knee osteoarthritis.
  - obesity and, 131, 143–157
  - pathogenesis of
    - bone in, 25–35, 37–42
    - causes of, 1–23
    - joint mechanics in, 65–80
  - pathophysiology of, 84–86
  - prevention of
drugs for, 6–7
exercise in, **159–175**
protective mechanisms in, 7–12
severity of, scoring systems for, 100
shoulder, 105–106
spinal, 52, 108
symptoms of, **81–98**
treatment of. *See also* Pain, management of.
analgesics in, 199–203
conservative, **125–141**
disease-modifying osteoarthritis drugs for, **221–232**
exercise in. *See* Exercise.
goals of, 128–129
intra-articular injections in, 134, 203–205, 226
noninvasive devices in, **177–198**
nonpharmacologic, 130, 132–133, 137
pharmacologic, 133–135, 137–138
physiologic interventions in, 16–18
recommendations for, 129–130, 132–136
surgical, 135–136, 138, **211–220**

Osteoarthritis Initiative study, 13, 47
Osteoarthritis Research Society International
  atlas of, 100
  treatment guidelines of, 129–136, 151

Osteophytes, 31–32
  radiography of, 100
  ultrasonography in, 102–103

Osteoprotegerin, 54

Osteotomy, 16, 73–74, 135, 213–215

**P**

Pain, **81–98**
as diagnostic criteria, 83–84
central mechanisms in, 88–89
constitutional factors in, 91–92
differential diagnosis of, 128
environmental factors in, 92–93
factors contributing to, 84
in physical examination, 83
innervation and, 86–88
management of
  analgesics for, 199–201
  nonsteroidal anti-inflammatory drugs for, 134, 201–202
  physiologic interventions in, 16–18
  topical agents in, 202–203
pathogenesis of, 12–16
pathophysiology of, 84–86
perception of, 88–89
sensitization to, 89–91
Patellar taping, 185–189
Patellofemoral arthrosis, 214
Patellofemoral replacement, 217
Physical activity. See Exercise.
Physical Activity, Inflammation, and Body Composition Trial, 149
Physical therapy, 137
Plantar fasciitis, in obesity, 146
Positron emission tomography, 104
Pralnascan, 227
Proprioception, in knee osteoarthritis, 163, 165
Prostaglandins, 52, 87
Psychologic factors, in pain, 91–92

Q
Quadriceps muscle
   exercises for, 168–169
   protective function of, 9–10
   weakness of, 163–164

R
Radiography, 83, 99–101, 127
   in joint mechanics studies, 68–69
   severity scoring systems for, 100
   versus clinical symptoms, 12–13
Radionuclide studies, 104
RHOB protein, 54
Risedronate, 225

S
Salicylates, 202
Scintigraphy, 104
Self-efficacy, 91
Sensitization, to pain, 89–91
Shoulder arthritis, 105–106
Social factors, in pain, 91–92
Spinal cord, hyperexcitability of, 90
Spinal osteoarthritis
   genetic factors in, 52
   magnetic resonance imaging in, 108
Structure-modifying drugs. See Disease-modifying osteoarthritis drugs.
Subchondral bone
   changes in, 29–30
   pain originating in, 14–16
   shock absorbing function of, 10–12
Substance P, in pain, 87
Surgery, 135–136, 138, 211–220
Sympathetic nervous system, in pain, 91
Synovitis, 13–14, 86, 225
Tanezumab, 226
Taping, for knee osteoarthritis, 16–17, 185–189
Tetracyclines, 224
Tetranectin, 54
Thioredoxin domain containing, 54
Tibial osteotomy, 73–74, 213–214
Tibial tubercle, elevation of, for patellofemoral arthrosis, 214
Tibiofemoral malalignment, 181–185
Tidemark, 25–26, 30
Topical agents, for pain, 202–203
Total knee replacement, 217–218
Trabecular bone, changes in, 29–30
Tramadol, 200
Triamcinolone, intra-articular, 203
Tumor necrosis factor inhibitors, 226
Twin studies, 46–50

U

Ultrasonography, 102–103
Unicompartmental arthroplasty, 215–217
UniSpacer device, 215
Unloader brace, 181–185

V

Vasoactive intestinal peptide, in pain, 87
Viscoelastic insoles, 190
Vitamin D, 226
Vitamin D receptor, 54–55
Vitamin K, 204

W

Walkers, for knee osteoarthritis, 178–181
Weakness
  in knee osteoarthritis, 161–164
  in obesity, 144
Weather, pain related to, 93
Wedged insoles, 190–193
Weight loss, for osteoarthritis, 131, 148–152
Wind-up concept, in pain, 90–91
Wnt proteins, 54–55